Research Impact Report 2021
The research that Ataxia UK funds has a real impact on the world of ataxia research, and our understanding of all ataxias. Every year we ask Ataxia UK-funded researchers to […]
Research Impact Report 2021 Read More »
Covid-19 vaccine: Boosters
Following the successful rollout of the Covid-19 vaccine, some people who are at higher risk of serious illness from Covid-19 are now being offered a booster vaccine dose. This booster dose of
Covid-19 vaccine: Boosters Read More »
Ataxia UK Annual Conference: Gluten-free diet tips for gluten ataxia patients
At the 2021 Ataxia UK Annual Conference, there was an interesting session from Professor Marios Hadjivassiliou and Emma Foster on immune and gluten ataxias. During the Q and A session, Emma
Ataxia UK Annual Conference: Gluten-free diet tips for gluten ataxia patients Read More »
New research suggests a reason for a delayed age of onset in some people with Friedreich’s ataxia: Full interview with researcher Dr Suran Nethisinghe
The Ataxia Magazine Issue 215 reported on a new paper on Friedreich’s ataxia (FA) from the team led by Professor Paola Giunti at the London Ataxia Centre, which has been
Development and Validation of a Patient-Reported Questionnaire of Ataxia Progression
In the clinic, assessment of cerebellar ataxias has been largely confined to clinical rating scales (e.g. Scale for Assessment and Rating of Ataxia -SARA-), gait laboratories, imaging of the brain,
Development and Validation of a Patient-Reported Questionnaire of Ataxia Progression Read More »
Reata Pharmaceuticals – Omaveloxolone Update
Update 17/11/2022 Omav data presented at the International Congress for Ataxia Research (ICAR 2022 – Dallas, Texas) Dr David Lynch, from the University of Pennsylvania and Children’s Hospital of Philadelphia,
Reata Pharmaceuticals – Omaveloxolone Update Read More »
New paper published on lower urinary tract and bowel dysfunction in spinocerebellar ataxias
A new paper from the team at the London Ataxia Centre provides new information on symptoms of the lower urinary tract (LUT) and the bowel in people with spinocerebellar ataxias (SCAs). The lower urinary tract consists of
New Ataxia Consortium created to accelerate the development of treatments for the Ataxias
Ataxia UK, along with Ataxia Global Initiative and National Ataxia Foundation, recently partnered with Critical Path Institute (C-Path) for the launch of their Critical Path to Therapeutics for the Ataxias
Neuromodulation of the cerebellum rescues movement in a mouse model of ataxia
The International Neuromodulation Society defines therapeutic neuromodulation as “the alteration of nerve activity through targeted delivery of a stimulus, such as electrical stimulation or chemical agents, to specific neurological sites
Neuromodulation of the cerebellum rescues movement in a mouse model of ataxia Read More »